Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
29 Febbraio 2024 - 12:30AM
Business Wire
Live and Archived Fireside Chat Available at
VirtualInvestorConferences.com
Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the
“Company”) announces that Chief Executive Officer Pietro
Bersani, Chief Financial Officer Brian Hungerford and Chief
Scientific Officer and Interim Operations Officer Leonardo
Mirandola, Ph.D., will participate in the OTC Markets’ Life Science
Investor Forum in a Fireside Chat format, hosted by
VirtualInvestorConferences.com, on March 7th, 2024.
Date: March 7, 2024 Time: 11:00
a.m. Eastern time Link: https://bit.ly/3OM3m93 Available
for 1x1 meetings: March 7, 2024
This will be a live, interactive event where investors are
invited to ask the company questions in real-time. An archived
webcast will also be available after the event.
Investors are invited to pre-register and run a system check to
expedite participation and receive event updates. For more
information, please visit www.virtualinvestorconferences.com.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary
investor conference series that provides an interactive forum for
publicly traded companies to seamlessly present directly to
investors.
Providing a real-time investor engagement solution, VIC is
specifically designed to offer companies more efficient investor
access. Replicating the components of an on-site investor
conference, VIC offers companies enhanced capabilities to connect
with investors, schedule targeted one-on-one meetings and enhance
their presentations with dynamic video content. Accelerating the
next level of investor engagement, Virtual Investor Conferences
delivers leading investor communications to a global network of
retail and institutional investors.
About Kiromic BioPharma
Kiromic BioPharma, Inc. is a clinical-stage, fully integrated
biotherapeutics company using its proprietary DIAMOND® artificial
intelligence (AI) 2.0 target discovery engine to develop and
commercialize cell therapies focusing on immuno-oncology. Kiromic
is developing a multi-indication allogeneic cell therapy platform
that exploits the natural potency of Gamma Delta T-cells to target
solid tumors. Kiromic’s DIAMOND® AI is where data science meets
target identification to dramatically compress the years and
hundreds of millions of dollars required to develop a live drug.
The Company maintains offices in Houston, Texas. To learn more,
visit www.kiromic.com and connect with us on Twitter and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240228415761/en/
Kiromic BioPharma Linda Phelan Dyson, MPH Global Head,
Corporate Communications ldyson@kiromic.com 281-468-7683
LHA Investor Relations Tirth T. Patel tpatel@lhai.com
212-201-6614
Virtual Investor Conferences John M. Viglotti SVP
Corporate Services, Investor Access OTC Markets Group (212)
220-2221 johnv@otcmarkets.com
Grafico Azioni Kiromic BioPharma (NASDAQ:KRBP)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Kiromic BioPharma (NASDAQ:KRBP)
Storico
Da Gen 2024 a Gen 2025
